Inhibition of myocardial cell death by novel chemicals and peptides through desacyl-ghrelin dependent-pathway

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K06597
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47040:Pharmacology-related
• Research Institution: Kagoshima University
• Principal Investigator: Koyama Hirofumi 鹿児島大学, 医歯学総合研究科, 客員研究員 (40709656)
• Co-Investigator(Kenkyū-buntansha): 上園 保仁 東京慈恵会医科大学, 医学部, 教授 (20213340)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: ドキソルビシン / 心毒性 / グレリン / 受容体 / ゼブラフィッシュ

Outline of Final Research Achievements

We were inspired that a desacyl-ghrelin,a kind of peptide hormone can reduce the cardiotoxicity of the doxorubicin (anti-cancer drug). We explored and identified the receptor of the hormone. We further identified　several　chemicals and artificial peptides that interacted with the receptor of the hormone. Administration of these molecules with doxorubicin might lower the cytotoxicity of doxorubicin.

Free Research Field

分子生物学

Academic Significance and Societal Importance of the Research Achievements

ドキソルビシンの毒性を抑えつつ、十分な量の投与を行うことができれば、がんの化学療法を心毒性のために途中で中止することなく最後まで実施でき、奏効する可能性が高くなり、がん患者のより良い生活に貢献できると考えられる。